Cargando…
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological processes, indicating the potential for common approaches to treatment. Nintedanib (Ofev(®)), an intracellular tyrosine kinase inhibitor (TKI) with antifibrotic properties, was one of the first drugs approved...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163683/ https://www.ncbi.nlm.nih.gov/pubmed/33765296 http://dx.doi.org/10.1007/s40265-021-01487-0 |